
Agreement - January 7, 2014
Shire extends expiration of tender offer for all outstanding shares of ViroPharma
Shire announces that it has extended the expiration of its previously announced tender offer by a wholly owned subsidiary of Shire for all of the outstanding common shares of ViroPharma until midnight, New York City time, on Thursday, January 9, 2014 (one minute after 11:59 p.m., New York City time, on January 9, 2014). The […]

Drug Development Pharma - September 4, 2013
Shire extends partnership with Santaris Pharma
The two companies extend their existing partnership in rare genetic disease space. The Danish clinical stage biopharmaceutical company Santaris Pharma focuses on the discovery and development of RNA-targeted therapies. Under the terms of agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development and Santaris will receive an upfront […]

Biotech Business - March 27, 2013
Shire acquires Premacure
Shire has acquired biotech company Premacure, developer of a drug to treat a rare eye disorder among premature infants.